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Edited by Robert BaroukiAbstract To test the role of the leukocyte common antigen-re-
lated protein tyrosine phosphatase (LAR) as a regulator of insu-
lin receptor (IR) signalling, an siRNA probe against LAR was
developed. Knock-down of LAR induced post-receptor insulin
resistance with the insulin-induced activation of PKB/Akt and
MAP kinases markedly inhibited. The phosphorylation and
dephosphorylation of the IR and insulin receptor substrate
(IRS) proteins were unaﬀected by LAR knock-down. These re-
sults identify LAR as a crucial regulator of the sensitivity of
two key insulin signalling pathways to insulin. Moreover, the
siRNA probe provides a molecular tool of general applicability
for further dissecting the precise targets and roles of LAR.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The leukocyte common antigen-related (LAR) protein is a
widely expressed receptor-like protein tyrosine phosphatase
(PTP) that has been implicated in the regulation of a diverse
range of cell signalling pathways [1].
To facilitate the further study of LAR, we now report the de-
sign of an siRNA probe that selectively suppresses LAR
expression in the human epithelial-like cell line HEK293.
The probe was used to test the role of LAR as a regulator of
insulin signalling. The results identiﬁed LAR as a key regulator
of post-receptor insulin signalling with LAR knock-down
inducing insulin resistance.2. Materials and methods
2.1. siRNA design
The p-Silencere 1.0-U6 siRNA expression vector (Ambion, Hun-
tingdon, UK) was used. Potential target sequences for LAR were se-
lected from the mouse database (gi11761807) that were also common
to human (gi18860871) and rat (gi9507012). Parameters for selecting
siRNA sequences were according to manufacturers guidelines. Se-
quences originated 50–100 nucleotides downstream of the initiationAbbreviations: IGF, insulin-like growth factor; IR, insulin receptor;
IRS, insulin receptor substrate; LAR, leukocyte common antigen-
related protein tyrosine phosphatase; PTP, protein tyrosine phosphatase
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doi:10.1016/j.febslet.2005.04.057site (avoiding regulatory proteins), had a GC content between 45%
and 55%, with a sense structure of AA (N19), and TTTT/AAAA
avoided (terminates transcription). BLAST searches conﬁrmed that
the sequences were LAR speciﬁc, particularly avoiding of any sequence
similarity with closely related LAR-family members PTPr and PTPd.
Four suitable test sequences were selected, corresponding to nucleotide
positions 4030, 4224, 5098 and 5170 (named L1, L2, L3 and L4, respec-
tively). The most active of these, L3, was based on the sequence 5 0-
GGCCTACATAGCTACACAG-3 0. Control siRNA constructs were
designed using mismatch (MM) and scrambled (SCR) sequences to
L3 (5 0-GGCCTAGATACCTACTCAG-3 0 and 5 0-GGTCACTAACG-
ACTAGACC-3 0, respectively).
2.2. Cell culture and transfections
Human embryonic kidney (HEK293) cells were obtained from the
European Collection of Cell Cultures (LGC Promochem, Teddington,
UK). HEK293 Cells were cultured in Dulbeccos modiﬁed Eagles
medium: HAMs nutrient medium (50:50), 10% heat inactivated horse
serum and 1% L-glutamine (Sigma, Poole, UK), at 37 C under 5%
CO2. Tissue culture ﬂasks and 12-well plates were pre-coated with
1:10 dilution of poly-L-lysine (Sigma). Cells were transfected with the
p-Silencere constructs using Gene Juicee transfection reagent (7 ll/
2 lg DNA) according to the manufacturers protocol (Novagen, Not-
tingham, UK). Cells were transfected at 60–80% conﬂuency.
2.3. Immunoblotting
Immunoblotting was carried out as described previously [2,3].
Where necessary, blots were quantiﬁed by densitometric scanning.
The anti-PTPa antibody has been described [2]. Other antibodies were
from the sources indicated in parentheses: anti-phospho Akt and anti-
phospho-p42/44MAPK (NEB, Hitchin, UK); anti-MAP kinase
(ERK1, ERK2) (Cambridge Bioscience, Cambridge, UK); anti-insulin
receptor (IR) b-subunit and anti-insulin receptor substrate (IRS) anti-
bodies (Upstate, Milton Keynes, UK); anti-LAR and anti-PTP1B (BD
Biosciences, Oxford, UK); anti-TC-PTP (Sigma).3. Results
3.1. Inhibition of LAR expression by siRNA
LAR expression was speciﬁcally inhibited using RNAi tech-
niques. The p-Silencere vector was used to create siRNA
targeted at LAR (see Section 2). Four diﬀerent constructs
(L1– L4) were designed and tested for eﬀectiveness in suppress-
ing LAR expression in HEK293 cells. Twenty-four hours after
transfection there was little eﬀect (Fig. 1A), but after 48 h two
of the four constructs, L3 and L4, decreased the amount of
detectable LAR by 70 ± 2.6% and 59 ± 3.5%, respectively, com-
pared to controls containing transfection reagent only (Fig. 1A
andB). Themost active construct, L3,was used in all subsequent
experiments, and mismatch (MM) and scrambled (SCR) se-
quences were designed as control siRNAs to test for non-speciﬁc
eﬀects of theL3 siRNAconstruct.Neither of the siRNAcontrols
caused decreased LAR expression (Fig. 1B). Immunoblottingblished by Elsevier B.V. All rights reserved.
Fig. 1. Speciﬁc inhibition of LAR expression in HEK293 cells by
siRNA. (A) Anti-LAR blot. Cells were analysed 24 and 48 h after
transfection with four diﬀerent siRNA constructs, targeted against
LAR (L1–L4), or treatment with transfection reagent alone (GJC).
(B) Anti-LAR blot showing LAR expression in cells treated for 48 h
with transfection reagent alone (GJC), L3, L4, L3-mismatch (MM) or
L3-scrambled (SCR) siRNA constructs. Blot shown is representative
of at least four independent experiments. (C) As B except cells were
immunoblotted for other major PTPs, including, PTPa, PTPe, PTP1B
and TC-PTP. (D) Phosphotyrosine (pY) immunoblot of immunopu-
riﬁed b-catenin from cells treated for 48 h with transfection reagent
(GJC), L3 siRNA and L3-mismatch (MM) constructs. Total b-catenin
and LAR immunoblots from the same samples are shown to indicate
equal loading and knock-down of LAR, respectively. Immunoblots
shown are representative of two individual experiments.
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TC-PTP. The expression of all four of these PTPs remained
unaﬀected by siRNA treatment (Fig. 1C). The eﬃcacy of the
L3 siRNA probe was validated by showing that LAR knock-
down markedly increased the tyrosine phosphorylation of
endogenous b-catenin [4] by5-fold with the mismatch control
ineﬀective (Fig. 1D). Thus, an eﬀective molecular tool for
studying LAR has been developed.3.2. LAR depletion does not alter insulin-induced tyrosine
phosphorylation of IR or IRS
Experiments were conducted to rigorously test whether the
IR and the IRS-proteins are substrates for LAR in vivo.
The eﬀects of LAR depletion on insulin-stimulated tyrosine
phosphorylation of the IR and IRS proteins was examined
ﬁrst. For this, cells were incubated in the presence or absence
of 100 nM insulin for 10 min. The IR was detected on anti-
phosphotyrosine immunoblots as an insulin-sensitive band at
97 kDa (Fig. 2A(i)). The identity of the IR b subunit was con-
ﬁrmed by the absence of the band after immunoprecipitation
with an IR b subunit speciﬁc antibody, in comparison to con-
trol immunoprecipitations in which the antibody was omitted
(results not shown). The antibody used has no reactivity
against the insulin-like growth factor (IGF)-I receptor whose
b-subunit comigrates with the IR b-subunit. Thus, insulin
was acting through the IR and not the IGF-I receptor in our
experiments. A strong insulin-sensitive band was also observed
at 185 kDa, which after immunoprecipitation were conﬁrmed
to be IRS-1 and IRS-2. LAR suppression did not signiﬁcantly
alter the insulin-stimulated tyrosine phosphorylation of either
the IR or IRS proteins (Fig. 2A(ii)). To study the eﬀect of
LAR depletion on the rate of dephosphorylation of the IR
and IRS proteins, time courses of dephosphorylation were
determined. Dephosphorylation rates were similar in all the
test conditions (Fig. 2B). The eﬀect of LAR knock-down on
the steady-state tyrosine phosphorylation of the IR b-subunit
and the IRS-proteins over a range of insulin concentrations
was also examined. This was important as measurement of
the steady-state may be expected to magnify the eﬀects of
depleting a PTP that dephosphorylates these substrates. If
LAR was controlling the phosphotyrosine status of the IR
or IRS proteins, LAR removal would be expected to increase
their sensitivity to insulin (i.e., shift the dose–response curve to
the left). However, L3 did not signiﬁcantly aﬀect the level of IR
or IRS tyrosine phosphorylation at any of the insulin concen-
trations tested, when compared to controls (Fig. 2C). These
observations suggest that LAR is unlikely to be an important
modulator of the tyrosine phosphorylation of IR or IRS in
HEK293 cells.3.3. Eﬀects of density-dependent changes in LAR expression on
IR phosphorylation
LAR expression is known to increase with increases in cell
density [5,6]. This natural increase in LAR expression provided
a further way of testing whether LAR regulates IR tyrosine
phosphorylation in vivo. HEK293 cells were seeded at low,
medium and high cell densities and harvested 18 h later, having
reached conﬂuencies of 25%, 45–50% and 95–100%, respec-
tively. LAR expression was 3.5-fold higher in the most conﬂu-
ent cells when compared to low density cells (Fig. 3A). IR
expression also increased and was 2-fold higher in the more
Fig. 2. LAR depletion does not alter insulin-induced tyrosine phos-
phorylation of IR or IRS proteins. (A): (i) Anti-phosphotyrosine blot
showing tyrosine phosphorylation of the IR and IRS proteins before
and after stimulation with 100 nM insulin for 10 min. HEK293 cells
were treated with transfection reagent only (GJC), L3, L3-mismatch
(MM) or L3-scrambled (SCR) siRNA sequences. Blots conﬁrmed
extensive depletion of LAR by L3 (72 ± 5%) with no depletion of LAR
in the controls. Results are representative of at least 4 experiments.
(ii) Histogram representation of fold-increases in the tyrosine phos-
phorylation of the IR and IRS proteins from above experiments, as
determined by densitometry. Transfection condition is indicated on the
graph. (B) Anti-phosphotyrosine blots showing rates of dephospho-
rylation of the IR and IRS proteins. Following 10 min stimulation
with 100 nM insulin, the medium was removed and replaced with
serum free medium. Dephosphorylation was allowed to proceed for 0,
1, 3, 5 and 7 min: (i) cells treated with transfection reagent only (GJC);
(ii) cells treated with L3. Blots conﬁrmed extensive depletion of LAR
by L3 (65 ± 6%). (C) Dose–response curves for tyrosine phosphory-
lation of the IR b-subunit and IRS-proteins. Cells were treated with
transfection reagent only (GJC, h) or L3 (j), and incubated with 0, 1,
10, 50 or 100 nM insulin for 10 min. The extents of tyrosine
phosphorylation of the IR (top two lines) and IRS proteins (lower
two lines) were determined by densitometry from anti-phosphotyrosine
immunoblots. LAR knockout by L3 was 74 ± 5%.
ig. 3. Eﬀects of density-dependent changes in LAR expression on
sulin signalling. (A) Anti-LAR blot of cells grown at low (25%),
edium (45–50%) and high (95–100%) cells densities. Equal amounts
f protein were loaded in each lane. (B) Anti-phosphotyrosine blot of
w and high density cells before and after stimulation with 100 nM
sulin for 10 min, showing insulin-induced increases in tyrosine
hosphorylation of the IR and IRS proteins. (C) Corresponding blots
gainst the IR b-subunit. Immunoblots representative of at least 3
dependent experiments.
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increased cell conﬂuency have not been previously reported.
The increased IR expression was matched by an increase in
the level of insulin-stimulated tyrosine phosphorylation
of the IR of 1.95-fold (Fig. 3B). Thus, natural increases in
endogenous LAR expression did not inhibit IR tyrosine phos-
phorylation. These results independently conﬁrm those ob-
tained by siRNA knock-down.
3.4. LAR knock-down induces insulin resistance
Knock-down of LAR by the L3 siRNA probe markedly
inhibited the insulin-stimulated increase in the phosphoryla-
tion of protein kinase B (PKB, also called Akt) on serine 473
by >90% (Fig. 4A). Control mismatch and scrambled siRNAs
were without eﬀect. Phosphorylation of PKB on serine 473 is
well known to reﬂect the activity of the kinase. Total PKB lev-
els were not altered by any transfection condition (Fig. 4A).
Furthermore, the PI3-kinase-independent phosphorylation of
MAP kinase in response to insulin was virtually abolished in
LAR-knock-down cells (Fig. 4B). Again, control mismatch
and scrambled siRNAs were without eﬀect and the total
amount of MAP kinase was not altered by any transfection
condition (Fig. 4B). These results show that LAR knock-down
has a profound inhibitory eﬀect on the signalling by the two
major pathways utilised by insulin with removal of LAR
inducing insulin resistance. The insulin resistance induced by
removal of LAR was genuine insulin resistance because signal-
ling responses to serum growth factors were unaﬀected, e.g.,Fig. 4. LAR knock-down induces insulin resistance. Cells were treated
with Gene Juice only (GJC), L3, L3-mismatch (MM) or L3-scrambled
(SCR) siRNA sequences for 48 h and incubated for the ﬁnal 10 min in
the presence or absence of 100 nM insulin. Samples were immuno-
blotted as indicated. (A) Anti-phospho PKB (ser 473) and anti-total
PKB antibodies. (B) Anti-phospho MAP kinase and anti-total MAP
kinase antibodies. Other blots showed that LAR knock-down by L3
was 72 ± 4%. Results are representative of at least 3 experiments.there was no decrease in DNA synthesis in response to serum
growth factors, a response that is known to be transduced by
the MAP kinase pathway (data not shown) [3].4. Discussion
LAR is a transmembrane receptor-like PTP with a wide tis-
sue distribution. It has been implicated in the regulation of
various signalling pathways triggered by growth factors, such
as insulin [1]. To facilitate the study of the signalling role of
LAR, we now report the development of an siRNA probe that
targets LAR. The siRNA probe achieved 70% knock-down of
LAR in HEK293 cells (Fig. 1). Other PTPs, such as PTPa,
PTPe, PTP1B or TC-PTP, that have also been implicated in
the regulation of growth factor receptor signalling, were not
depleted by the siRNA probe. The siRNA probe was then used
to test the role of LAR in regulating insulin signalling.
Knock-down of LAR induced post-receptor insulin resis-
tance with the insulin-induced activation of PKB/Akt and
MAP kinases markedly inhibited in the absence of eﬀects on
the phosphorylation or dephosphorylation of the IR or IRS
proteins. The insulin resistance induced by removal of LAR
was genuine insulin resistance because signalling responses to
serum growth factors were unaﬀected (data not shown), e.g.,
there was no decrease in DNA synthesis in response to serum
growth factors, a response that is known to be transduced by
the MAP kinase pathway [3]. Our results identify LAR as a
regulator of the sensitivity of two key insulin signalling path-
ways to insulin. Moreover, the siRNA probe provides a molec-
ular tool of general applicability for further dissecting the
precise targets and roles of LAR.
Our results parallel the observation that expression of a cat-
alytically in-active PTP, Shp-2, blocked the insulin-stimulated
activation of MAP kinase [7]. Shp-2 appeared to act by target-
ing a protein downstream of p21ras [7].
Whether LAR dephosphorylates the IR has been an area of
controversy with initial studies in model cell systems in favour
of such a role [8,9]. Thus, antisense suppression of LAR, to a
similar level achieved by our siRNA probe, increased IR auto-
phosphorylation and reduced the rate of IR dephosphoryla-
tion in rat hepatoma cells [8,9]. The diﬀerence between these
results and those herein may be due to use of diﬀerent cell
types or that the long antisense sequence (546 bases) imposed
non-speciﬁc knockout eﬀects on PTPs besides LAR. More
recently, two diﬀerent transgenic mice studies failed to ﬁnd evi-
dence that LAR acts on the IR. In one study insulin-stimulated
hepatic tyrosine phosphorylation of the IR and IRS-1 was not
signiﬁcantly increased in LAR (/) mice compared to wild
type animals [10]. In another mouse model where LAR was
overexpressed in muscle there was no change in the tyrosine
phosphorylation of either the IR or IRS-1 [11]. For the ﬁrst
time, our results support the transgenic mice studies in a model
cell system.
The insulin resistance induced by siRNA triggered LAR
knock-down is supported by post-receptor signalling defects
observed in a LAR knockout mice study [10]. These mice dis-
played signiﬁcant resistance to the eﬀects of insulin at the PI3-
kinase level. However, the signiﬁcance of the LAR knockout
mice results alone was uncertain because of the potential for
changes in the expression of an array of proteins in the long
term knockout models. Consequently, it was unclear whether
3028 A. Mander et al. / FEBS Letters 579 (2005) 3024–3028the insulin resistance in the LAR knockout mice was directly
attributable to removal of LAR or a secondary or compensa-
tory eﬀect. Our results now clearly show in an isolated cell sys-
tem that direct removal of LAR in the short term induces
insulin resistance and thereby establish a new role for LAR.
A major challenge for the future will be to identify the targets
for LAR that mediate this eﬀect.Acknowledgement: This work was supported by Diabetes UK.References
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